ESMO 2019 | TNBC treatment: platinum-based therapy and PARP inhibition

Véronique Dieras

Véronique Dieras, MD, Eugène Marquis Center, Rennes, France, talks about BRCA mutations in triple-negative breast cancer (TNBC) and the promising response to cytotoxic platinum-based chemotherapy and PARP inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics
Related videos
2:59
BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer
Véronique Dieras
2:13
HER-2 conversion: a phenomenon in trastuzumab resistance
Russell Petty
1:45
Real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
Felice Musicco
4:18
IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC
David Spigel
1:58
Targeted therapy in TNBC
Peter Schmid
Breast Cancer
ESMO 2019
Interview
27th September 2019
More from Véronique Dieras
BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals